$EXEL
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$EXEL
Exelixis Inc.
$EXELNASDAQHealthcareMid-Cap
Exelixis develops cancer treatments including Cabometyx and has a growing oncology pipeline.
Market Cap
$8.5B
Revenue (TTM)
$2.0B
+18.0%
Net Income (TTM)
$0.4B
+25.0%
EPS (TTM)
$1.30
P/E Ratio
22.0
Dividend Yield
0.0%
52-Week Range
$20-$38
Beta
0.72
Dimension Scores
Fundamental
70Technical
68Sentiment
72Risk / Reward
70Momentum
72Financial Health
Profitability
75moderate
Growth
75strong
Liquidity
78strong
Solvency
72strong
Efficiency
68strong
Valuation, technical analysis, investment thesis, risk assessment and more for $EXEL
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.